VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 132 filers reported holding VANDA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 2.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $554,000 | +18.9% | 33,794 | -3.7% | 0.02% | -32.0% |
| Q3 2019 | $466,000 | -11.4% | 35,097 | -6.0% | 0.02% | +25.0% |
| Q2 2019 | $526,000 | -22.4% | 37,350 | +1.3% | 0.02% | -48.7% |
| Q1 2019 | $678,000 | +189.7% | 36,854 | +199.6% | 0.04% | +680.0% |
| Q2 2018 | $234,000 | -41.8% | 12,300 | -48.5% | 0.01% | -28.6% |
| Q1 2018 | $402,000 | -84.6% | 23,900 | -83.7% | 0.01% | -76.7% |
| Q3 2017 | $2,616,000 | +245.6% | 146,200 | +214.4% | 0.03% | +172.7% |
| Q2 2017 | $757,000 | +177.3% | 46,500 | +90.6% | 0.01% | -15.4% |
| Q2 2016 | $273,000 | +129.4% | 24,400 | +70.6% | 0.01% | +116.7% |
| Q1 2016 | $119,000 | -70.2% | 14,300 | -59.6% | 0.01% | -80.0% |
| Q3 2015 | $399,000 | +44.6% | 35,400 | +62.4% | 0.03% | -28.6% |
| Q2 2015 | $276,000 | -61.7% | 21,800 | -50.9% | 0.04% | +23.5% |
| Q1 2014 | $721,000 | – | 44,400 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |